Jaka jest cena za Boundless Bio, Inc. (BOLD)

Cena za Boundless Bio, Inc. (BOLD) wynosi $3.00

Jaka jest kapitalizacja rynkowa dla Boundless Bio, Inc. (BOLD)

Kapitalizacja rynkowa dla Boundless Bio, Inc. (BOLD) wynosi $67.31M

Boundless Bio, Inc. (BOLD) Stopa Dywidendy

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

Rok	Stopa dywidendy	Zmień
Za mało danych dla podanych dat.

Rok

Stopa dywidendy

Zmień

Za mało danych dla podanych dat.

Firma	Stopa dywidendy	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH

Firma

Stopa dywidendy

Kraj

Vertex Pharmaceuticals Incorporated

VRTX.US

0.00%

Argenx SE

ARGX.US

0.00%

Moderna, Inc.

MRNA.US

0.00%

CSL Limited

CSL.AX

3.12%

Lonza Group AG

LONN.SW

0.00%

Boundless Bio, Inc.

BOLD

Kategoria